Patient-reported efficacy of adjunctive brexpiprazole in major depressive disorder in a phase 4, open-label, interventional study
Patient-reported diary data revealed early and sustained improvements in depressive symptom severity during 8 weeks of adjunctive brexpiprazole treatment. 'Word of the day' may be an effective qualitative tool for future trials.
Authors
- Zahinoor Ismail (ORCID: https://orcid.org/0000-0002-5529-3731)
- Jeffrey Habert (ORCID: https://orcid.org/0000-0003-0009-3182)
- Jennifer Dine (ORCID: https://orcid.org/0000-0002-2121-9752)
- Caroline Ward (ORCID: https://orcid.org/0000-0001-8362-4713)
- François Therrien (ORCID: https://orcid.org/0000-0002-6512-4333)
- Erin M. MacKenzie
- Roger S. McIntyre (ORCID: https://orcid.org/0000-0003-4733-2523)
- Zhen Zhang (ORCID: https://orcid.org/0000-0002-6512-1458)
- Pratap Chokka (ORCID: https://orcid.org/0000-0002-1043-8554)
- T. Michelle Brown (ORCID: https://orcid.org/0000-0002-4580-805X)
Institutions
- Global Affairs Canada (CA)
- Allen Institute for Brain Science (US)
- University of Alberta (CA)
- University of Calgary (CA)
- University of Toronto (CA)
- Patient-Centered Outcomes Research Institute (US)
- Otsuka (United States) (US)
- O'Brien Institute (AU)
- Translational Research in Oncology (CA)
- RTI Health Solutions (US)
- Quest Center for Integrative Health (US)
- Otsuka Pharmaceutical (Spain) (ES)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-08-03
- DOI
- https://doi.org/10.1080/03007995.2025.2558140
- Citations
- 1
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 1.39